Exelixis
EXEL
$0.26 (1.20%)
1D
1W
3M
1Y
5Y
ALL
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Business Wire • 9 hours ago • EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in MayZacks Investment Research • 2 days ago • EXEL
Exelixis (EXEL) International Revenue Performance ExploredZacks Investment Research • 7 days ago • EXEL
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall ShortSeeking Alpha • 7 days ago • EXEL
Exelixis, Inc. (EXEL) Q1 2024 Earnings Call TranscriptZacks Investment Research • 7 days ago • EXEL
Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to SayCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.